Advertisement


Benjamin Besse, MD, PhD, on NSCLC: A Vaccine Under Study to Treat Advanced Disease

ESMO Congress 2021

Advertisement

Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, discusses final phase III findings from the Atalante-1 trial, which explored the question of whether the OSE2101 vaccine is more beneficial than standard treatment for patients with HLA-A2–positive non–small cell lung cancer after immune checkpoint inhibitors are no longer effective (Abstract LBA47).



Related Videos

COVID-19

Jonathan Lim, MBBS, MRCP: The Future of the Oncology Workforce Since the COVID-19 Pandemic

Jonathan Lim, MBBS, MRCP, of Christie NHS Foundation Trust and the Francis Crick Institute, discusses results of an ESMO survey, which showed that the risk of poor well-being, distress, and burnout has continued to rise since the onset of the COVID-19 pandemic, despite improved job performance and sustained resilience. Those most at risk, he says, are women aged 40 years and younger (Abstract 561O).

Breast Cancer

Gabriel N. Hortobagyi, MD, on Advanced Breast Cancer Treated With Endocrine Therapy and Ribociclib

Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses results from the MONALEESA-2 trial, which showed that adding the CDK4/6 inhibitor ribociclib to first-line hormonal therapy prolongs survival by 1 year for postmenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer. As a result, he believes it should be considered the preferred treatment option (Abstract LBA17).

 

Kidney Cancer
Immunotherapy

Toni K. Choueiri, MD, on Renal Cell Carcinoma: Quality-of-Life Data From KEYNOTE-564 on Pembrolizumab vs Placebo

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses patient-reported outcomes for quality of life in the KEYNOTE-564 study, which previously met its primary endpoint of disease-free survival with adjuvant pembrolizumab vs placebo following surgery for renal cell carcinoma (Abstract 653O).

Breast Cancer
Immunotherapy

Hope S. Rugo, MD, on Triple-Negative Breast Cancer: Treatment Findings From KEYNOTE-355 on Pembrolizumab and Chemotherapy

Hope S. Rugo, MD, of the University of California, San Francisco, discusses phase III results from the KEYNOTE-355 study of pembrolizumab plus chemotherapy, which improved overall survival vs chemotherapy alone in patients with previously untreated locally recurrent, inoperable, or metastatic triple-negative breast cancer whose tumors expressed PD-L1 (Abstract LBA16).

Breast Cancer
Immunotherapy

Javier Cortés, MD, PhD, on HER2-Positive Breast Cancer: Trastuzumab Deruxtecan vs Trastuzumab Emtansine

Javier Cortés, MD, PhD, of Barcelona’s IOB Institute of Oncology, discusses phase III data from the DESTINY-Breast03 study, which support trastuzumab deruxtecan becoming the standard of care for second-line treatment of women with HER2-positive metastatic breast cancer (Abstract LBA1).

Advertisement

Advertisement




Advertisement